India Pharma Outlook Team | Monday, 27 April 2026
Cohance Lifesciences has appointed Umang Vohra as its new Executive Chairman and Group CEO, marking a major leadership shift aimed at driving growth.
The company said Umang Vohra will take charge as Executive Chairman from May 1, 2026, and step in as Group CEO from May 20, 2026. This move places Cohance Lifesciences at a critical turning point as it looks to strengthen its global position.
Vohra succeeds Vivek Sharma, who has stepped down from his role for personal reasons. However, Sharma will continue to support the company as an advisor for the next nine months to ensure a smooth transition. The leadership change comes at a time when the company is looking to sharpen execution and accelerate expansion.
Also Read: Building Sustainable Pharma Growth through Ethical Marketing Practices
Vohra brings deep industry experience, having previously led Cipla Limited through a phase of global growth and transformation. His track record in scaling operations and building international partnerships is expected to play a key role in shaping the next phase of Cohance Lifesciences.
The appointment signals a clear strategic intent. The company aims to strengthen its presence in the contract development and manufacturing space while improving operational efficiency and commercial execution. With strong scientific capabilities already in place, the focus is now shifting toward scaling the business and delivering consistent growth.
The market responded quickly to the announcement, with investor sentiment turning positive on expectations of stronger leadership and improved performance. Vohra’s entry is widely seen as a move to unlock value and reposition the company for long-term growth.
With this leadership change, Cohance Lifesciences is betting on experienced guidance to navigate challenges and build a more competitive global footprint in the life sciences sector.
.jpg)
.jpg)
